Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis

Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis

Abstract Idiopathic pulmonary fibrosis (IPF) is a globally prevalent, progressive disease with limited treatment options and poor prognosis. Because of its irreversible disease progression, IPF affects the quality and length of life of patients and imposes a significant burden on their families and...

Full description

Bibliographic Details
Main Authors: Jie Tan, Qianfei Xue, Xiao Hu, Junling Yang
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Journal of Translational Medicine
Subjects:
PD-1
PD-L1
Immune checkpoint
Idiopathic pulmonary fibrosis
Mechanism of action
Treatment
Online Access:https://doi.org/10.1186/s12967-024-04884-7

Internet

https://doi.org/10.1186/s12967-024-04884-7

Similar Items